PK - Inhibikase gets dosing underway in early-stage IkT-148009 Parkinson's disease trial

Inhibikase Therapeutics (IKT) announces dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.The randomized Phase 1 study is investigating the safety, tolerability and pharmacokinetics (PK) of IkT-148009 in healthy volunteers aged 45 to 70 years old with the objective of identifying the maximum tolerated dose and the PK profile of IkT-148009 in single and multiple ascending dose settings.In preclinical animal models of progressive disease, the company showed that once a day oral therapy with IkT-148009 can both halt and reverse functional loss in the brain and gastrointestinal tract.Shares of the company up nearly 2% premarket.

For further details see:

Inhibikase gets dosing underway in early-stage IkT-148009 Parkinson’s disease trial